Brainomix AI Imaging Analysis of Phase 3 CHARM Trial Identifies Promising Treatment Signals in Severe Stroke Patients

Brainomix AI Imaging Analysis of Phase 3 CHARM Trial Identifies Promising Treatment Signals in Severe Stroke Patients

AI-powered analysis of Phase 3 CHARM trial suggests that Brainomix non-contrast CT (NCCT) technology may help identify severe stroke patients more likely to benefit from CIRARA, supporting more precise patient selection and the design of future stroke trials.

Data presented at the 18th World Stroke Conference (October 21 – 23, Seoul).